New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

›ETF Issuers›Tema›HRTS
HRTS

Tema GLP-1, Obesity & Cardiometabolic ETF

Active ETFEquityTheme: Tomorrow's Treatments
Not rated

The HRTS Exchange Traded Fund (ETF) is provided by Tema. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$36.90
-$0.34 (-0.92%) yesterday
1:30 PM 07/30/26 Closed
1D price range
$36.53$36.94
52W price range
$27.60$37.58
YTD Perf.
+5.43%
YTD Flows
Annualized volatility
Fund AuM
€48M
Share class AuM
€48M
TTM Yield
Tracking Error
Tracking Difference
Characteristics
ISIN
US87975E8839
TER
0.99%
Inception date
11/21/2023
Issuer
Tema
Dividend policy
Distributing
Compare similar ETFs
ETF Name1w perf.
MEDX
Horizon Kinetics Medical ETF
+2.14%
GDOC
Goldman Sachs Future Health Care Equity ETF
+1.75%
ZGHC
BMO Global Health Care Fund Active ETF Series
+3.04%
JDOC
JPMorgan Healthcare Leaders ETF
+3.56%
PBPH
Portfolio Building Block World Pharma and Biotech Index ETF
+3.72%
WEL9
Amundi S&P World Health Care Screened UCITS ETF
+4.47%
CBUF
iShares MSCI World Health Care Sector Advanced UCITS ETF
+4.27%
XDWH
Xtrackers MSCI World Health Care UCITS ETF
+4.07%
WHEA
State Street SPDR MSCI World Health Care UCITS ETF
+4.07%
IHE
iShares U.S. Pharmaceuticals ETF
+2.76%
XDG3
Xtrackers MSCI Global SDG 3 Good Health UCITS ETF
+4.84%
AGNG
Global X Aging Population ETF
+3.89%
WDHE
Invesco S&P World Health Care ESG UCITS ETF
+4.52%
IXJ
iShares Global Healthcare ETF
+4.30%
IXJ
iShares Global Healthcare ETF (AU)
+5.35%
API
PerformanceDec 31, 2025 - Jul 29, 2026
-5%0%5%JANMARMAYJUL
Flows
Join for free to unlock
Sector exposures
Data as of 06/30/26
Healthcare
99.57%
Unavailable
0.43%
Latest HRTS news
Ozempic and Weight Loss Drug ETFs Back in Spotlight After Key Earnings Results
Moving Markets · August 12, 2024

FAQ about HRTS

HRTS is a Active ETF. This ETF provides exposure to Other Equities.
HRTS carries a total expense ratio (TER) of 0.99%, indicating the annual cost for holding the fund.
HRTS was introduced to the market on November 21, 2023. It trades on United States
Tema GLP-1, Obesity & Cardiometabolic ETF, HRTS, is provided by Tema. Learn more about Tema here.
HRTS oversees €48M in assets as of July 29, 2026.
HRTS follows a distributing dividend policy, meaning it pays out income to investors. As of July 29, 2026, its 12-month trailing yield was 1.27%.
As of June 30, 2026, HRTS has significant geographic allocations in USA, Switzerland and Denmark.
As of June 30, 2026, HRTS focuses largely on Healthcare.
As of June 30, 2026, HRTS holds 43 positions in its portfolio, with 64.29% of assets concentrated in its top 15 holdings.
As of June 30, 2026, HRTS top three holdings include Eli Lilly & Co., UnitedHealth Group, Inc. and Novo Nordisk A/S.
The base currency of HRTS is USD.
Top 10 holdings
Data as of 06/30/26
Eli Lilly & Co.
11.91%
UnitedHealth Group, Inc.
5.58%
Novo Nordisk A/S
5.25%
Merck & Co., Inc.
4.11%
Roche Holding AG
3.96%
Thermo Fisher Scientific, Inc.
3.91%
AstraZeneca PLC
3.85%
Johnson & Johnson
3.84%
Revolution Medicines, Inc.
3.64%
Cytokinetics, Inc.
3.40%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
ETF TOOLS
ETF ScreenerCompare ETFsCompare ETF issuersWatchlistsETF Portfolio InsightsIndustry dataETF stock exposure finder
PLATFORM
Support and feedback
ETF NEWS & RESEARCH
Latest ETF NewsETF Research ReportsGlobal ETF Survey 2025Learn ETF investing
PROFESSIONAL SOLUTIONS
Enterprise SolutionsDue Diligence ServicesETF Data Services
SOLUTIONS FOR
Institutional investorsPrivate banksFinancial advisorsFintech and mediaIndividual investors
CONTACT US
General inquiries
Press and media
Advertising opportunities
Support and feedback
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Get our newsletters
Trackinsight